UroGen Pharma Ltd
URGN
Market Cap$478.6M
Close$
$15.60
53.9% upside
Current Fair Value
53.9% upsideUndervalued by 53.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $478.60 Million |
|---|---|
| Enterprise Value | $430.00 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.96 |
| Beta | 0.67 |
| Outstanding Shares | 47,030,820 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.85 |
|---|---|
| PEG | -46.93 |
| Price to Sales | 10.14 |
| Price to Book Ratio | -10.14 |
| Enterprise Value to Revenue | 4.81 |
| Enterprise Value to EBIT | -5.12 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | -14.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About UroGen Pharma Ltd
CEO: Elizabeth Barrett